Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J. C., Vaishampayan, U. N., De Wit, R., … de Bono, J. S. (2021). 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. In Annals of Oncology (Vol. 32, pp. S651–S652). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1124

Antonarakis, E. S., J. M. Piulats, M. Gross-Goupil, J. C. Goh, U. N. Vaishampayan, R. De Wit, T. V. Alanko, et al. “611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study.” In Annals of Oncology, 32:S651–52. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1124.

Antonarakis ES, Piulats JM, Gross-Goupil M, Goh JC, Vaishampayan UN, De Wit R, et al. 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. In: Annals of Oncology. Elsevier BV; 2021. p. S651–2.

Antonarakis, E. S., et al. “611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S651–52. Crossref, doi:10.1016/j.annonc.2021.08.1124.

Antonarakis ES, Piulats JM, Gross-Goupil M, Goh JC, Vaishampayan UN, De Wit R, Alanko TV, Fukasawa S, Tabata K, Feyerabend S, Berger R, Ojamaa K, Hoimes CJ, Sezer A, Omlin AG, Yachnin J, Niu C, Poehlein CH, Schloss C, de Bono JS. 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Annals of Oncology. Elsevier BV; 2021. p. S651–S652.